AgingResearch.NewsJoin free

Cell Genesys

CompanyUnited States

Cell Genesys develops one asset, in phase 3 (IRX-2 in prostate cancer). Mostly vaccine acting on inflammation; based in the United States.

1
Asset
Furthest stage
Phase 3
3
Trials
0
Signals

Pipeline

1

  • IRX-2

    Allogeneic whole-cell prostate cancer vaccine expressing GM-CSF to stimulate anti-tumor immune response

    Phase 3, Vaccine, Inflammation, prostate cancer, squamous cell carcinoma of the oral cavity (Phase 2)

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms2
  • Trials3
  • Similar companies6

Intelligence